stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Book value per share
Tarsus Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 8.2×, up 37.7% from 6.0× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 2.2×. Over the past ten years it has ranged from 0.1× (fiscal 2018) to 26.7× (fiscal 2020); the current reading is higher than 75% of that period. Tarsus Pharmaceuticals, Inc. ranks 264th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 8.2× | 37.65% |
| FY2024 | 6.0× | (10.94%) |
| FY2023 | 6.7× | (14.44%) |
| FY2022 | 7.8× | (3.41%) |
| FY2021 | 8.1× | (69.67%) |
| FY2020 | 26.7× | 10.09% |
| FY2019 | 24.3× | 21,338.57% |
| FY2018 | 0.1× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 2.2× | (71.95%) |
| Jun 2026 | 8.0× | (1.64%) |
| Mar 2026 | 8.1× | (1.17%) |
| Dec 2025 | 8.2× | 4.51% |
| 25 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.0× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| DNLI Denali Therapeutics Inc. compare | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. | 2.2× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement